- Home
- CRBU vs DIBS Comparison
CRBU vs DIBS Comparison
Compare CRBU & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBU | DIBS |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 153.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRBU | DIBS |
|---|---|---|
| Price | $1.68 | $5.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $10.75 | $7.00 |
| AVG Volume (30 Days) | ★ 1.8M | 161.2K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.64 | ★ 22.45 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $89,620,000.00 |
| Revenue This Year | $1.63 | $3.12 |
| Revenue Next Year | $10.93 | $1.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.54 |
| 52 Week Low | $1.22 | $2.50 |
| 52 Week High | $3.53 | $6.62 |
Technical Indicators
Market Signals| Indicator | CRBU | DIBS |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 70.66 |
| Support Level | $1.39 | $4.92 |
| Resistance Level | $1.73 | $6.18 |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 28.05 | 97.72 |
Price Performance
Historical ComparisonAbout CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.